Skip to content Skip to sidebar Skip to footer

Finding New Ways Off the Beaten Path

Q ed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium loremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. …

Read more

Biopharma Deal Terminations Top 20 2018 - 19

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…

Read more

The Blues Kitchen Podcast

Q ed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium loremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. …

Read more

Insights+ Key Biosimilars Events of November 2019

Insights+ Key Biosimilars Events of November 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]